ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print September 5, 2007
Eur Respir J 2007, doi:10.1183/09031936.00042107
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
30/6/1103    most recent
09031936.00042107v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thenappan, T
Right arrow Articles by Gomberg-Maitland, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thenappan, T
Right arrow Articles by Gomberg-Maitland, M.


ORIGINAL ARTICLE

A united states-based registry for pulmonary arterial hypertension: 1982–2006

T Thenappan 1, S.J. Shah 1, S. Rich 1, M. Gomberg-Maitland 1*

1 Section of Cardiology, Dept of Medicine, University of Chicago, Chicago, IL

* To whom correspondence should be addressed. E-mail: mgomberg{at}medicine.bsd.uchicago.edu.


   Abstract

We aimed to define the epidemiology of World Health Organization (WHO) Group I pulmonary arterial hypertension (PAH) in a large referral center in the United States (US).

The Pulmonary Hypertension Connection registry, initiated in 2004, evaluated all patients in a single US practice from 1982–2006. For comparison, we divided the group by incident vs. prevalent cohorts, by etiology, and by treatment era.

578 patients, age 48±14 years, 77% female, and 80% with class III or IV symptoms were entered. Over time, connective tissue disease (CTD)-associated PAH increased, while referrals for human immunodeficiency virus (HIV) remained low. One-third of patients were referred on calcium channel blocker (CCB) therapy even though only 4.6% had an acute response to vasodilator challenge. When compared by treatment era, there were no differences in the severity of PAH. However, survival has improved over time, with a 1-year survival of 85% in the incident cohort.

In the US, PAH patients are still referred to tertiary centers late. Referral of CTD is increasing, while referral of HIV remains low. Inappropriate CCB treatment is common. Survival rates have increased but remain low suggesting that prognosis is improving but PAH is still a progressive, fatal disease.

Keywords:  Epidemiology, etiology, medications, survival, pulmonary arterial hypertension




This article has been cited by other articles:


Home page
NEJMHome page
S. L. Archer and E. D. Michelakis
Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension
N. Engl. J. Med., November 5, 2009; 361(19): 1864 - 1871.
[Full Text] [PDF]


Home page
Eur Respir JHome page
R. Wensel, C. Jilek, M. Dorr, D. P. Francis, H. Stadler, T. Lange, F. Blumberg, C. Opitz, M. Pfeifer, and R. Ewert
Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension
Eur. Respir. J., October 1, 2009; 34(4): 895 - 901.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc IntervHome page
G. Yong, P. Khairy, P. De Guise, A. Dore, F. Marcotte, L.-A. Mercier, S. Noble, and R. Ibrahim
Pulmonary Arterial Hypertension in Patients With Transcatheter Closure of Secundum Atrial Septal Defects: A Longitudinal Study
Circ Cardiovasc Interv, October 1, 2009; 2(5): 455 - 462.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. J. Shah, M. Gomberg-Maitland, T. Thenappan, and S. Rich
Selective Serotonin Reuptake Inhibitors and the Incidence and Outcome of Pulmonary Hypertension
Chest, September 1, 2009; 136(3): 694 - 700.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
S. J. Shah, T. Thenappan, S. Rich, J. Sur, S. L. Archer, and M. Gomberg-Maitland
Value of Exercise Treadmill Testing in the Risk Stratification of Patients With Pulmonary Hypertension
Circ Heart Fail, July 1, 2009; 2(4): 278 - 286.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
V. V. McLaughlin, D. B. Badesch, M. Delcroix, T. R. Fleming, S. P. Gaine, N. Galie, J. S. R. Gibbs, N. H. Kim, R. J. Oudiz, A. Peacock, et al.
End Points and Clinical Trial Design in pulmonary arterial hypertension.
J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S97 - 107.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Gomberg-Maitland
Something Subtle About Death: Isolated Systolic Pulmonary Pressure
Circulation, May 26, 2009; 119(20): 2647 - 2649.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association
J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1573 - 1619.
[Full Text] [PDF]


Home page
CirculationHome page
Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association
Circulation, April 28, 2009; 119(16): 2250 - 2294.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. Humbert
Update in Pulmonary Hypertension 2008
Am. J. Respir. Crit. Care Med., April 15, 2009; 179(8): 650 - 656.
[Full Text] [PDF]


Home page
ERRHome page
M. Humbert
More pressure on pulmonary hypertension
Eur. Respir. Rev., March 1, 2009; 18(111): 1 - 3.
[Full Text] [PDF]


Home page
ERRHome page
R. Souza and C. Jardim
Trends in pulmonary arterial hypertension
Eur. Respir. Rev., March 1, 2009; 18(111): 7 - 12.
[Full Text] [PDF]


Home page
ChestHome page
S. M. Kawut, N. Al-Naamani, C. Agerstrand, E. Berman Rosenzweig, C. Rowan, R. J. Barst, S. Bergmann, and E. M. Horn
Determinants of Right Ventricular Ejection Fraction in Pulmonary Arterial Hypertension
Chest, March 1, 2009; 135(3): 752 - 759.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
R. W. Schrier and S. Bansal
Pulmonary Hypertension, Right Ventricular Failure, and Kidney: Different from Left Ventricular Failure?
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1232 - 1237.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
M. Gomberg-Maitland
Traditional and Alternative Designs for Pulmonary Arterial Hypertension Trials
Proceedings of the ATS, July 15, 2008; 5(5): 610 - 616.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. M. Chin and L. J. Rubin
Pulmonary arterial hypertension.
J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1527 - 1538.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. Humbert
Update in Pulmonary Arterial Hypertension 2007
Am. J. Respir. Crit. Care Med., March 15, 2008; 177(6): 574 - 579.
[Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. L. Archer, M. Gomberg-Maitland, M. L. Maitland, S. Rich, J. G. N. Garcia, and E. K. Weir
Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1{alpha}-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H570 - H578.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the European Respiratory Society.